SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Company Response from NANOVIRICIDES, INC. (NNVC) (CIK 0001379006) (NNVC) — Jan 9, 2020

NANOVIRICIDES, INC. (NNVC) (CIK 0001379006)
Date: Jan. 9, 2020 · CIK: 0001379006 · Accession: 0001104659-20-002474

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-235306

Date
January 9, 2020
Author
Joseph T. Rallo
Form
CORRESP
Company
NANOVIRICIDES, INC. (NNVC) (CIK 0001379006)

Letter

Re: NanoViricides, Inc.

January 9, 2020

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Registration Statement on Form S-1, as amended

File No. 333-235306

Ladies and Gentlemen:

As representative of the underwriters of the proposed public offering of common stock of NanoViricides, Inc. (the “Company”), we hereby join the Company’s request that the effective date of the above-referenced Registration Statement on Form S-1 be accelerated so that it will be declared effective at 4:00 p.m., Eastern time, on Thursday, January 9, 2020, or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission.

Pursuant to Rule 460 of the General Rules and Regulations under the Securities Act of 1933, as amended, we wish to advise you that we intend to effect the following distribution of the Company’s Preliminary Prospectus dated January 8, 2020, through the time of effectiveness:

Preliminary Prospectus dated January 6, 2020:

200 copies to prospective underwriters, institutional investors, dealers and others

The undersigned advise that they have complied and will continue to comply, and that they have been informed by the participating underwriters and dealers that they have complied with and will continue to comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.

Very truly yours,
AEGIS CAPITAL CORP.

Show Raw Text
CORRESP
1
filename1.htm

January 9, 2020

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

 Re: NanoViricides, Inc.

  Registration Statement on Form S-1, as amended

  File No. 333-235306

Ladies and Gentlemen:

As representative of
the underwriters of the proposed public offering of common stock of NanoViricides, Inc. (the “Company”), we
hereby join the Company’s request that the effective date of the above-referenced Registration Statement on Form S-1 be accelerated
so that it will be declared effective at 4:00 p.m., Eastern time, on Thursday, January 9, 2020, or at such later time as the Company
or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and
Exchange Commission.

Pursuant to Rule 460
of the General Rules and Regulations under the Securities Act of 1933, as amended, we wish to advise you that we intend to effect
the following distribution of the Company’s Preliminary Prospectus dated January 8, 2020, through the time of effectiveness:

Preliminary Prospectus
dated January 6, 2020:

 200 copies to
prospective underwriters, institutional investors, dealers and others

The undersigned advise
that they have complied and will continue to comply, and that they have been informed by the participating underwriters and dealers
that they have complied with and will continue to comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act
of 1934, as amended.

Very truly yours,

AEGIS CAPITAL CORP.

By: /s/ Joseph T. Rallo

Name: Joseph T. Rallo

Title: Co-Head of Investment Banking